Pfizer holds steady with a 6.7% dividend yield amid pipeline transition and debt concerns.

Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining COVID revenues, rising costs, and a heavy debt load from recent acquisitions. Management remains optimistic about new drug pipelines, but investors are advised to hold and collect dividends while monitoring upcoming trial results and debt management. The consensus target price is $29.19, suggesting moderate upside potential.